Nuformix PLC (LSE:NFX) said it will carry out further inhalation studies of NXP002, one of its lead assets, which will be delivered using a new method to address issues faced in recent duration-of-action studies.
NXP002, a reformulated version of the antiallergic drug Tranilast, is being developed as a potential inhaled treatment for idiopathic pulmonary fibrosis.
Beginning in August, the further studies are part of its plans to generate a robust pre-clinical data package to support the progression of NXP002, both in terms of product development and business development discussions, the company said, after the inconclusive results of a recent study.
Firstly, Nuformix said it will investigate a new formulation of NXP002 for inhalation, delivered using an alternative method designed to ensure consistent and controlled exposure is achieved.
Then it will explore a new range of doses to best optimise efficacy of treatment.
“The eventual aim of the studies is to confirm the formulation's positive pharmacological profile towards the treatment of lung fibrosis and inflammation via inhalation and to assess its duration of action,” the company said.
Results are expected to be generated throughout the second half of 2022 as development milestones are achieved.
“NXP002 is our lead programme and after the frustrations of the study undertaken earlier this year from which no conclusions could be drawn, I am pleased that we are back on track to investigate the product opportunity further,” said non-executive director Dr Julian Gilbert.
“The planned programme of studies is intended to ensure we have a robust pre-clinical data package for NXP002 to support the further progression of this asset. I look forward to providing further updates in due course as we progress."